This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mukhopadhyay, U. K. Articles by Ferbeyre, G. Search for Related Content PubMed PubMed Citation Articles by Mukhopadhyay, U. K. Articles by Ferbeyre, G.

RNA Silencing of Checkpoint Regulators Sensitizes p53-Defective Prostate Cancer Cells to Chemotherapy while Sparing Normal Cells

¹ Département de Biochimie, Université de Montréal, Montreal, Quebec, Canada and ² Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, Maryland

Requests for reprints: Gerardo Ferbeyre, Département de Biochimie, Université de Montréal, E-515 C.P. 6128, Succursale Centre-Ville, Montreal, Quebec, Canada H3C 3J7. Phone: 514-343-7571; Fax: 514-343-2210; E-mail: g.ferbeyre{at}umontreal.ca.

p53 is frequently mutated in patients with prostate cancer, especially in those with advanced disease. Therefore, the selective elimination of p53 mutant cells will likely have an impact in the treatment of prostate cancer. Because p53 has important roles in cell cycle checkpoints, it has been anticipated that modulation of checkpoint pathways should sensitize p53-defective cells to chemotherapy while sparing normal cells. To test this idea, we knocked down ataxia telangiectasia mutated (ATM) gene by RNA interference in prostate cancer cell lines and in normal human diploid fibroblasts IMR90. ATM knockdown in p53-defective PC3 prostate cancer cells accelerated their cell cycle transition, increased both E2F activity and proliferating cell nuclear antigen expression, and compromised cell cycle checkpoints, which are normally induced by DNA damage. Consequently, PC3 cells were sensitized to the killing effects of the DNA-damaging drug doxorubicin. Combining ATM knockdown with the Chk1 inhibitor UCN-01 further increased doxorubicin sensitivity in these cells. In contrast, the same strategy did not sensitize either IMR90 or LNCaP prostate cancer cells, both of which have normal p53. However, IMR90 and LNCaP cells became more sensitive to doxorubicin or doxorubicin plus UCN-01 when both p53 and ATM functions were suppressed. In addition, knockdown of the G₂ checkpoint regulators ATR and Chk1 also sensitized PC3 cells to doxorubicin and increased the expression of the E2F target gene PCNA. Together, our data support the concept of selective elimination of p53 mutant cells by combining DNA damage with checkpoint inhibitors and suggest a novel mechanistic insight into how such treatment may selectively kill tumor cells.

Key Words: Chemosensitivity • Prostate cancer • ATM • E2F • PCNA • G₂ checkpoint • p53 • shRNA

This article has been cited by other articles:

				H. Jiang, H. C. Reinhardt, J. Bartkova, J. Tommiska, C. Blomqvist, H. Nevanlinna, J. Bartek, M. B. Yaffe, and M. T. Hemann The combined status of ATM and p53 link tumor development with therapeutic response Genes & Dev., August 15, 2009; 23(16): 1895 - 1909. [Abstract] [Full Text] [PDF]

				A. R. Demidova, M. Y. Aau, L. Zhuang, and Q. Yu Dual Regulation of Cdc25A by Chk1 and p53-ATF3 in DNA Replication Checkpoint Control J. Biol. Chem., February 13, 2009; 284(7): 4132 - 4139. [Abstract] [Full Text] [PDF]

				D. J. Burgess, J. Doles, L. Zender, W. Xue, B. Ma, W. R. McCombie, G. J. Hannon, S. W. Lowe, and M. T. Hemann Topoisomerase levels determine chemotherapy response in vitro and in vivo PNAS, July 1, 2008; 105(26): 9053 - 9058. [Abstract] [Full Text] [PDF]

				D. Wilsker and F. Bunz Loss of ataxia telangiectasia mutated- and Rad3-related function potentiates the effects of chemotherapeutic drugs on cancer cell survival Mol. Cancer Ther., April 1, 2007; 6(4): 1406 - 1413. [Abstract] [Full Text] [PDF]

				Y. Sylvestre, V. De Guire, E. Querido, U. K. Mukhopadhyay, V. Bourdeau, F. Major, G. Ferbeyre, and P. Chartrand An E2F/miR-20a Autoregulatory Feedback Loop J. Biol. Chem., January 26, 2007; 282(4): 2135 - 2143. [Abstract] [Full Text] [PDF]

				F. A. Mallette, M.-F. Gaumont-Leclerc, and G. Ferbeyre The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence Genes & Dev., January 1, 2007; 21(1): 43 - 48. [Abstract] [Full Text] [PDF]

				R. P Singh and R. Agarwal Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr. Relat. Cancer, September 1, 2006; 13(3): 751 - 778. [Abstract] [Full Text] [PDF]

				O. Moiseeva, F. A. Mallette, U. K. Mukhopadhyay, A. Moores, and G. Ferbeyre DNA Damage Signaling and p53-dependent Senescence after Prolonged beta-Interferon Stimulation Mol. Biol. Cell, April 1, 2006; 17(4): 1583 - 1592. [Abstract] [Full Text] [PDF]

				M. Mimeault and S. K. Batra Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies Carcinogenesis, January 1, 2006; 27(1): 1 - 22. [Abstract] [Full Text] [PDF]